GlassScriptPhysician profile
Marlo Brawner
NPI 1033218730
$3,925.31
in general payments reported to CMS, 2019-2025
19 companies · $642 in 2025
The $642 reported for 2025 was more than what 95% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $371 · 2021: $664 · 2022: $751 · 2023: $473 · 2024: $879 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $967.06 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $892.10 | 2020-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $647.62 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $609.14 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $168.23 | 2020-2021 | |
| Cranial Technologies, INC | $149.95 | 2020-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $112.62 | 2022-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Pfizer INC. | $112.58 | 2020-2025 | |
| Sanofi Pasteur INC. | $60.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $31.49 | 2019-2022 | |
| Baxter Healthcare | $30.94 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Shire North American Group INC | $24.80 | 2019 | |
| Genentech USA, INC. | $22.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.44 | 2023 | Flumist Quadrivalent |
| Neurelis, INC. | $19.53 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.29 | 2025 | |
| Vertical Pharmaceuticals, LLC | $13.91 | 2019 | |
| Sobi, INC | $13.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlo Brawner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.